The research company Respiratorius reports, as planned, no revenue for the first quarter of 2026. Profit after financial items improved to SEK -1.7 million (-2.0). Earnings per share amounted to SEK -0.21 (-0.39). The company says that the focus during the quarter has been business development around the drug candidate VAL001. According to CEO Johan Drott, several meetings were held with pharmaceutical companies in connection with BIO Europe Spring 2026 and several counterparties are now evaluating the project internally. Respiratorius further states that the European patent for the oral formulation of VAL001 has been granted and that the company assesses current financing as sufficient until February 2027. Respiratorius, SEK millionQ1 2026Q1 2025Profit before tax-1.7-2.0Net profit-1.7-2.0Earnings per share, SEK-0.21-0.39